Efficacy of intranasal application of povidone-iodine cream in eradicating nasal methicillin-resistant Staphylococcus aureus in neonatal intensive care unit (NICU) staff.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 8290448.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We investigated the staff in our neonatal intensive care unit (NICU) for the presence of methicillin-resistant Staphylococcus aureus (MRSA) in the nasal cavity, and then applied intranasal povidone-iodine cream to the physicians and nurses working on the unit. Prior to the application of povidone-iodine cream, the isolation rate of S. aureus from the nasal cavity was 30% for the physicians and nurses in contact with NICU patients (contact group), not significantly different from the 33.3% rate for other hospital staff (control group). The isolation rate for the contact group decreased to 10.5% after application of the cream. Although MRSA was not isolated from the nasal cavity of those in the control group, it was isolated from 13.3% of those of the contact group before application of the cream. Nasal MRSA disappeared after use of the cream. No adverse reactions or abnormalities in serum levels of thyroid hormone-related substances were observed in any of the subjects. These results indicated that the nasal application of povidone-iodine cream is safe and effective for eradicating MRSA in the nasal cavity.
Medical subject headings
- Carrier State
- Infectious Disease Transmission, Professional-to-Patient
- Nasal Cavity
- Povidone-Iodine
- Staphylococcal Infections